BASF Keen on Leveraging Dow-DuPont Deal?

The plot surrounding the proposed merger of Dow and DuPont continues to thicken.

After the companies late last week signaled that the deal could take longer due to regulatory inquiries, rumors quickly resurfaced that heavyweight BASF was and possibly still is interested in sticking its foot into the door.

International media reports say BASF has sought advice from financial advisers – some of them named Deutsche Bank and Citgroup – on how best to launch a counter bid for Syngenta.

It is unclear whether this meant the German group was hoping to outbid Monsanto or ChemChina, the buyer that eventually won the race. Earlier reports that said BASF was weighing a joint bid with Monsanto, would point to the latter.

In a regulatory filing with the US Securities and Exchange Commission (SEC) at the beginning of this month, DuPont said it had discussed a full or partial merger with several unidentified companies before sealing a deal with US rival Dow last December.

Despite the “big and bigger” rumours – BASF is world’s largest chemical producer by sales – most observers believe, that at this point, the German group may be only looking to acquire some of the assets Dow or DuPont would have to divest to appease antitrust authorities.

Only a complete merger with DuPont would give BASF access to the seeds portfolio some analysts think it could be seeking. Speaking against this theory are recent remarks by CEO Kurt Bock that it is happy to concentrate on seed traits and leave product development and marketing to Monsanto, with which it has a cooperation agreement.

If one of the parties to the Dow-DuPont merger breaks the deal it could be liable for a termination fee of $1.9 billion.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.